Diagnostic and therapeutic approach to cholestatic liver disease;Abordaje diagnóstico y terapéutico del síndrome colestásico

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 1, 2004, Pages 60-73

  Perez Fernandez T ^a   Lopez Serrano P ^a   Tomas E ^a   Gutierrez Ma L ^a   Lledo J L ^a   Cacho, G ^a   Santander, C ^a   Fernández Rodriguez, Conrado M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Cholangiography; Cholestasis; Pruritos; Ultrasonography; Ursodeoxycholic acid

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; AZATHIOPRINE; CALCIFEDIOL; CALCIUM DERIVATIVE; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; ETIDRONIC ACID; FLUMECINOL; METHOTREXATE; METHYLTESTOSTERONE; MYCOPHENOLIC ACID; NALMEFENE; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PHENOBARBITAL; PROPRANOLOL; RETINOL; RIFAMPICIN; SEROTONIN 3 ANTAGONIST; STEROID; THIAZIDE DIURETIC AGENT; THYROXINE; URSODEOXYCHOLIC ACID; VITAMIN K GROUP; WARFARIN;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALPHA TOCOPHEROL DEFICIENCY; ARTICLE; ASCITES; BILE ACID SYNTHESIS; BILE DUCT ATRESIA; BLEEDING; CHOLANGIOGRAPHY; CONSTIPATION; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG ANTAGONISM; DRUG BINDING; DRUG CHOICE; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FAMILY HISTORY; FIRST TRIMESTER PREGNANCY; HUMAN; HYPEREMESIS GRAVIDARUM; INTRAHEPATIC CHOLESTASIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALABSORPTION; METABOLIC DISORDER; NEVUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PHOTOTHERAPY; PLASMAPHERESIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; RISK FACTOR; RUBELLA; SEDATION; SIDE EFFECT; TOXOPLASMOSIS; VIRUS HEPATITIS;

EID: 1442301019     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082004000100008     Document Type: Article

References (55)

1. McIntyre N. Cholestasis. En: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J, eds. Oxford textbook of Clinical Hepatology. 2th ed. Oxford: Oxford Medical. Publications, 1999. p. 1574-9.
2. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
3. Sherlock S, Heathcote J. Primary biliary cirrhosis. En: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J, eds. Oxford textbook of Clinical Hepatology. 2th ed. Oxford: Oxford Medical. Publications, 1999. p. 1090-8.
4. Reshef R, Sbeit W, Lachter L. The chronic cholestasis enigma in adults. IMAJ 2002; 4: 449-53.
5. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 11-7.
6. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-32.
7. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90: 247-9.
8. Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL, et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995; 108: 1802-9.
9. Moreno A, Carreño V, Cano A, González C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997; 336: 835-8.
10. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998; 73: 285-91.
11. Mc Gill JM, Kwiatkowski AP. Cholestatic liver diseases in adults. Am J Gastroenterol 1998; 93: 684-91.
12. Demetris AJ. Immune cholangitis: liver allograft rejection and graft-versus-host disease. Mayo Clin Proc 1998; 73: 367-79.
13. Perera DR, Greene ML, Fenster LF. Cholestasis associated with extrabiliary Hodgkin's disease. Report of three cases and review of four others. Gastroenterology 1974; 67: 680-5.
14. Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24: 759-86.
15. De Leve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24: 787-810.
16. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-21.
17. Mason AL, Wick M, White HM, Benner KG, Lee RG, Regenstein F, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993; 105: 237-44.
18. Riely CA. Familial intrahepatic cholestatic syndromes. Semin Liver Dis 1987; 7: 119-33.
19. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000; 95: 1130-8.
20. DGleeson D, Boyer JL. Intrahepatic cholestasis. En: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J, eds. Oxford textbook of Clinical Hepatology. 2th ed. Oxford: Oxford Medical Publications, 1999. p. 1591-620.
21. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53.
22. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000; 32 (Supl. 1): 129-40.
23. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33: 949-52.
24. Datta DV, Sherlock S. Cholestyramine forlong term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50: 323-32.
25. Jschoenfield L, Sjovall J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967; 213: 93-8.
26. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: Relation to serum levels and to pruritus. Gastroenterology 1977; 73: 1125-30.
27. Ghent CN. Pruritus of cholestasis is related to effects to effects of bile salts on the liver, not the skin. Am J Gastroenterol 1987; 82: 117-8.
28. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. JAMA 1992; 268: 3359-62.
29. Jones E, Bergasa N. The pruritus of cholestasis. Hepatology 1999; 29: 1003-6.
30. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-7.
31. Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679-84.
32. Terg R, Coronel E, Sorda J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-22.
33. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-93.
34. Podesta A, López P, Terg R, Villamil F, Flores D, Mastai R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampicin. Dig Dis Sci 1991; 36: 216-20.
35. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-6.
36. Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994; 8: 337-42.
37. Raderer M, Müller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994; 330: 1540.
38. Schwörer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993; 341: 1277 [Letter].
39. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10: 865-70.
40. Neuberger J. Liver Transplantation for Cholestatic Liver Disease. Curr Treat Options Gastroenterol 2003; 6: 113-21.
41. Guañabens N, Pares A, Monegal A, Peris P, Pons F, Álvarez L, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113: 219-24.
42. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33: 878-82.
43. Pares A, Guañabens N, Ros I, Pons F, Álvarez L, Caballería L, et al. Alendronate versus etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment. J Hepatol 2001; 34 (Supl. 1): 19.
44. Le Gars L, Grandpierre C, Chazouilleres O, Berenbaum F, Poupon R. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine 2002; 69: 195-200.
45. Theal JJ, Toosi MN, Girlan LM, et al. Ondansetron ameliorates fatigue in patients with primary biliary cirrhosis (abstract). Hepatology 2002; 36: 296 A.
46. Goulis J, Leandro G, Burroughs AK. Randomized contrled trials of Ursodeoxycolic acid therapy for primary biliary cirrhosis. A meta-analysis. Lancet 1999; 354: 1053-60.
47. Gluud C, Christensen E. Ursodeoxycolic Acid for Primary Biliary Cirrhosis. (Cochrane review). Cochrane database Syst. Rev 2002; (1): CD000551.
48. Pares A, Caballería L, Rodes J, Bruguera M, Rodrigo L, García-Plaza A, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561-6.
49. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestasis diseases involving small bile ducts in adults. Am J of Gastroenterol 2000; 95: 1130-8.
50. Ben Ari Z, Dhilon AP, Sherlock S. Autoinmune cholangiopathy: parts of the spectrum of autoinmmune hepatitis. Hepatology 1993; 18: 10-5.
51. Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoinmmune cholangitis). Aliment Pharmacol Ther 2003; 17: 17-27.
52. Reshef R, Sbit W, Laxhter J. The chronic cholestasis enigma in adults. IMAJ 2002; 4: 449-53.
53. Sánchez-Pobre P. González C, Paz E, Colina F, Castellano G, Muñoz-Yagüe T, et al. Chronic hepatitis C and autoinmmune cholangitis: a case study and litteratue review. Dig Dis Sci 2002; 47 (6): 1224-9.
54. Linares Rodríguez A. Tratamiento médico, de la colestasis crónika: ácido ursodesoxicólico. Gastroenterol Hepatol 2000; 23 (Supl. 1): 24-38.
55. Qureshi WA. Intrahepatic cholestatic syndromes: pathogenesis, clinical features and management. Dig Dis 1999; 17: 49-59.